Wuhan YZY Biopharma (2496) Stock Overview

Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related eye diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma and other advanced solid tumors, small cell lung cancer, relapsed/refractory multiple myeloma, and HER2-positive solid tumors; and covid 19 indication, as well as wAMD, DME, and other ocular neovascularization-related diseases. The company was founded in 2010 and is based in Wuhan, China.